Inhibiting this oncogenic signature resulted in a BRD4-dependent reduction in PAH-PASMC proliferation accompanied by an elevation in apoptosis, suggesting that BRD4 overexpression is pathologically associated with PAH and may be a target for therapy (124). Here, BRD4 is linked to pulmonary arterial hypertension.